\u00c7ocuklarda otoimm\u00fcn ve otoinflamatuvar hastal\u0131klar\u0131n de\u011ferlendirilmesi ve tedavi yan\u0131t\u0131 \u00fczerine \u00e7al\u0131\u015fan bir \u00e7ocuk romatolojisi uzman\u0131n\u0131n EB-1A I-140 ba\u015fvurusu i\u00e7in USCIS onay\u0131 ald\u0131k. Dosyada klinik ara\u015ft\u0131rmalar\u0131n\u0131, dijital de\u011ferlendirme \u00e7al\u0131\u015fmalar\u0131n\u0131 ve mesleki tan\u0131n\u0131rl\u0131\u011f\u0131n\u0131 bir araya getirdik.<\/p>\n
Ara\u015ft\u0131rmalar\u0131n\u0131n belirgin bir ortak y\u00f6n\u00fc vard\u0131: Bir yandan tedaviye yeterli yan\u0131t vermeyebilecek \u00e7ocuklar\u0131n belirlenmesini, di\u011fer yandan hastal\u0131k kontrol\u00fc sa\u011fland\u0131ktan sonra tedavinin azalt\u0131lmas\u0131n\u0131 incelemek. Ba\u015fvurunun bilimsel anlat\u0131s\u0131n\u0131 bu sorular \u00fczerinden kurduk.<\/p>\n
M\u00fcvekkilimiz, \u00e7ocuk romatolojisi alan\u0131ndaki klinik \u00e7al\u0131\u015fmalar\u0131n\u0131 akademik e\u011fitim ve ara\u015ft\u0131rmayla birlikte s\u00fcrd\u00fcr\u00fcyor. Dosyada \u00f6ne \u00e7\u0131kan konulardan biri, tekrarlayan inflamatuvar ataklarla seyreden ailevi Akdeniz ate\u015fiydi (FMF).<\/p>\n
Ortak \u00e7al\u0131\u015fmalar\u0131ndan biri, tan\u0131 an\u0131ndaki bilgilerle kol\u015fisin direncini \u00f6ng\u00f6rmeye y\u00f6nelik bir skoru ele al\u0131yordu. Ara\u015ft\u0131rma ekibi, \u00e7ok merkezli hasta kay\u0131tlar\u0131ndan yararlanarak tedaviye yetersiz yan\u0131tla ili\u015fkili olabilecek klinik ve genetik \u00f6zellikleri inceledi.<\/p>\n
Ba\u015fvuruda skorun arkas\u0131ndaki soruyu a\u00e7\u0131klad\u0131k: Hastal\u0131\u011f\u0131n erken d\u00f6neminde elde edilen bilgiler, tedavi yan\u0131t\u0131n\u0131 de\u011ferlendirmeye nas\u0131l yard\u0131mc\u0131 olabilir? Ara\u015ft\u0131rman\u0131n risk \u00f6ng\u00f6r\u00fcs\u00fcne katk\u0131s\u0131n\u0131 anlat\u0131rken, m\u00fcvekkilimizin \u00e7al\u0131\u015fmadaki yerini ortak ara\u015ft\u0131rma i\u00e7inde sunduk.<\/p>\n
Dosyada, kol\u015fisine diren\u00e7li FMF hastalar\u0131nda kanakinumab tedavisinin azalt\u0131lmas\u0131 ve sonland\u0131r\u0131lmas\u0131n\u0131 inceleyen \u00e7al\u0131\u015fma da yer ald\u0131. Bu ara\u015ft\u0131rma, hastal\u0131k aktivitesi ve tekrar alevlenme izlenerek y\u00fcr\u00fct\u00fclen planl\u0131 bir yakla\u015f\u0131m\u0131 de\u011ferlendiriyordu.<\/p>\n
Bu \u00e7al\u0131\u015fma, tedaviye diren\u00e7 ara\u015ft\u0131rmas\u0131yla birlikte ele al\u0131nd\u0131\u011f\u0131nda bilimsel oda\u011f\u0131 daha net g\u00f6sterdi. Ara\u015ft\u0131rmalar, hem hastal\u0131k kontrol\u00fcn\u00fcn g\u00fc\u00e7lendirilmesi gereken durumlar\u0131 hem de se\u00e7ilmi\u015f ko\u015fullarda tedavinin azalt\u0131lma olas\u0131l\u0131\u011f\u0131n\u0131 inceliyordu. \u0130ki y\u00f6n\u00fc birlikte a\u00e7\u0131klamak, m\u00fcvekkilimizin ara\u015ft\u0131rma birikimini tutarl\u0131 bir anlat\u0131ya d\u00f6n\u00fc\u015ft\u00fcrd\u00fc.<\/p>\n
\u00c7ocukluk \u00e7a\u011f\u0131ndaki vask\u00fclit ve juvenil artrit gibi hastal\u0131klarda tedavi kararlar\u0131n\u0131 ele alan di\u011fer yay\u0131nlar\u0131 da bu \u00e7er\u00e7eveye yerle\u015ftirdik. B\u00f6ylece dosya farkl\u0131 makalelerin s\u0131raland\u0131\u011f\u0131 bir liste olmaktan \u00e7\u0131k\u0131p tedavi yan\u0131t\u0131, izlem ve bireysel de\u011ferlendirme etraf\u0131nda \u015fekillendi.<\/p>\n
M\u00fcvekkilimizin yay\u0131nlar\u0131 aras\u0131nda \u00e7ocuklar\u0131n kas-iskelet sistemi de\u011ferlendirmesinin video g\u00f6r\u00fc\u015fmesine uyarlanmas\u0131n\u0131 inceleyen bir \u00e7al\u0131\u015fma bulunuyordu. Ara\u015ft\u0131rma, yap\u0131land\u0131r\u0131lm\u0131\u015f bir muayenenin uzaktan uygulanmas\u0131n\u0131 ve de\u011ferlendirme \u00f6zelliklerini ele al\u0131yordu.<\/p>\n
\u00c7ocukluk \u00e7a\u011f\u0131nda lupus tan\u0131s\u0131na y\u00f6nelik yapay zek\u00e2 ara\u015ft\u0131rmas\u0131 ise klinik ve laboratuvar bilgilerinden yararlanan bir modeli inceliyordu. Bu iki \u00e7al\u0131\u015fmay\u0131, belirli y\u00f6ntem ve bulgular\u0131 olan ara\u015ft\u0131rmalar olarak sunduk. Dijital ara\u00e7lar\u0131n tan\u0131 ve izlemde nas\u0131l de\u011ferlendirilebilece\u011fi, dosyan\u0131n ayr\u0131 bir bilimsel y\u00f6n\u00fcn\u00fc olu\u015fturdu.<\/p>\n
Ara\u015ft\u0131rma gruplar\u0131na kat\u0131l\u0131m\u0131 ve ileri ara\u015ft\u0131rma e\u011fitimine y\u00f6nelik f\u0131rsatlar\u0131 da mesleki geli\u015fimi i\u00e7inde a\u00e7\u0131klad\u0131k. Bu belgeler \u00e7al\u0131\u015fmalar\u0131n\u0131 y\u00fcr\u00fctt\u00fc\u011f\u00fc bilimsel ortam\u0131 ve i\u015f birliklerini g\u00f6sterirken, ara\u015ft\u0131rmalar\u0131n katk\u0131s\u0131n\u0131 anlatan yay\u0131nlarla birlikte de\u011ferlendirildi.<\/p>\n
Kan\u0131tlar\u0131, her birinin bilimsel katk\u0131lar\u0131 veya mesleki tan\u0131n\u0131rl\u0131\u011f\u0131 hangi y\u00f6nden a\u00e7\u0131klad\u0131\u011f\u0131n\u0131 g\u00f6stererek sunduk.<\/p>\n
| Sunulan kan\u0131t<\/th>\n | Dosyada destekledi\u011fi unsur<\/th>\n<\/tr>\n<\/thead>\n |
|---|---|
| Hakemli bilimsel yay\u0131nlar<\/td>\n | Tedaviye diren\u00e7, biyolojik tedavinin sonland\u0131r\u0131lmas\u0131, \u00e7ocukluk \u00e7a\u011f\u0131ndaki inflamatuvar hastal\u0131klar ve dijital de\u011ferlendirme \u00e7al\u0131\u015fmalar\u0131n\u0131; m\u00fcvekkilimizin yazarl\u0131\u011f\u0131n\u0131 ve kat\u0131l\u0131m\u0131n\u0131 ortaya koydu.<\/td>\n<\/tr>\n |
| At\u0131f kay\u0131tlar\u0131 ve at\u0131f yapan yay\u0131nlar<\/td>\n | Ara\u015ft\u0131rmalar\u0131n bilimsel literat\u00fcrde g\u00f6rd\u00fc\u011f\u00fc ilgiyi ve sonraki \u00e7al\u0131\u015fmalarla ili\u015fkisini a\u00e7\u0131klayan arg\u00fcman\u0131 destekledi.<\/td>\n<\/tr>\n |
| Dergi hakemli\u011fi yaz\u0131\u015fmalar\u0131 ve faaliyet kay\u0131tlar\u0131<\/td>\n | Ba\u015fka ara\u015ft\u0131rmac\u0131lar\u0131n \u00e7al\u0131\u015fmalar\u0131n\u0131 de\u011ferlendirdi\u011fini g\u00f6steren unsurlar olarak sunuldu; belgelerin elverdi\u011fi \u00f6l\u00e7\u00fcde davet ve tamamlanan inceleme ayr\u0131\u015ft\u0131r\u0131ld\u0131.<\/td>\n<\/tr>\n |
| Bilimsel sunum \u00f6d\u00fclleri ve kongre belgeleri<\/td>\n | Belirli \u00e7al\u0131\u015fmalar\u0131n g\u00f6rd\u00fc\u011f\u00fc takdiri ve mesleki \u00e7evrelerde payla\u015f\u0131lmas\u0131n\u0131 belgeledi.<\/td>\n<\/tr>\n |
| Ara\u015ft\u0131rma grubu ve mesleki komite belgeleri<\/td>\n | Bilimsel i\u015f birliklerindeki kat\u0131l\u0131m\u0131n\u0131 ve belgelenen sorumluluklar\u0131n\u0131 a\u00e7\u0131klad\u0131.<\/td>\n<\/tr>\n |
| Ara\u015ft\u0131rma ziyareti destekleri ve e\u011fitim kay\u0131tlar\u0131<\/td>\n | Ara\u015ft\u0131rma geli\u015fimine ve i\u015f birliklerine sa\u011flanan deste\u011fi g\u00f6sterdi; bilimsel ba\u015far\u0131 \u00f6d\u00fcllerinden ayr\u0131 ele al\u0131nd\u0131.<\/td>\n<\/tr>\n |
| Yay\u0131mlanm\u0131\u015f haberler<\/td>\n | \u00c7al\u0131\u015fmalar\u0131na ve uzmanl\u0131\u011f\u0131na y\u00f6nelik ilgiyi, her i\u00e7eri\u011fin kapsam\u0131 i\u00e7inde ortaya koydu.<\/td>\n<\/tr>\n |
| Akademik ve klinik g\u00f6rev belgeleri<\/td>\n | Hekimlik, \u00f6\u011fretim ve ara\u015ft\u0131rma deneyiminin mesleki ba\u011flam\u0131n\u0131 a\u00e7\u0131klad\u0131.<\/td>\n<\/tr>\n |
| \u00c7al\u0131\u015fma plan\u0131<\/td>\n | \u00c7ocuk romatolojisi ve dijital sa\u011fl\u0131k ara\u015ft\u0131rmalar\u0131n\u0131 s\u00fcrd\u00fcrme hedeflerini belgelenen uzmanl\u0131\u011f\u0131yla ili\u015fkilendirdi.<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n Bu belgeleri birlikte sunarak, m\u00fcvekkilimizin alan\u0131nda s\u00fcreklilik g\u00f6steren tan\u0131n\u0131rl\u0131\u011fa ve ola\u011fan\u00fcst\u00fc yetene\u011fe sahip oldu\u011fu y\u00f6n\u00fcndeki ba\u015fvuru arg\u00fcman\u0131n\u0131 olu\u015fturduk. USCIS, I-140 ba\u015fvurusunu EB-1A kategorisinde onaylad\u0131.<\/p>\n Ara\u015ft\u0131rmac\u0131 hekimler i\u00e7in EB-1A de\u011ferlendirmesi<\/h2>\nM\u00fcvekkilimizin \u00e7al\u0131\u015fma plan\u0131, \u00e7ocuklarda otoimm\u00fcn ve otoinflamatuvar hastal\u0131klar, tedavi yan\u0131t\u0131 ve dijital izlem \u00fczerine ara\u015ft\u0131rmalar\u0131n\u0131 s\u00fcrd\u00fcrmeye odaklan\u0131yordu. Bu hedefleri, yay\u0131nlar\u0131nda ve ara\u015ft\u0131rma deneyiminde yer alan sorularla ili\u015fkilendirdik.<\/p>\n Siz de \u00e7ocuk sa\u011fl\u0131\u011f\u0131 veya ba\u015fka bir t\u0131p uzmanl\u0131k alan\u0131ndaki \u00e7al\u0131\u015fmalar\u0131n\u0131zla EB-1A ba\u015fvurusunu de\u011ferlendiriyorsan\u0131z, ki\u015fisel katk\u0131lar\u0131n\u0131z\u0131 ve g\u00f6rd\u00fckleri ilgiyi hangi belgelerle a\u00e7\u0131klayabildi\u011finizi birlikte inceleyebiliriz. Mesleki ge\u00e7mi\u015finiz ve ABD’deki \u00e7al\u0131\u015fma planlar\u0131n\u0131z hakk\u0131nda g\u00f6r\u00fc\u015fmek i\u00e7in us@celiksoylaw.com<\/a> adresinden bize ula\u015fabilirsiniz.<\/p>\n","protected":false},"excerpt":{"rendered":" \u00c7ocuklarda tedaviye direnci, biyolojik tedavinin azalt\u0131lmas\u0131n\u0131 ve dijital de\u011ferlendirme y\u00f6ntemlerini ara\u015ft\u0131ran bir \u00e7ocuk romatolojisi uzman\u0131 i\u00e7in EB-1A I-140 onay\u0131 ald\u0131k.<\/p>\n","protected":false},"featured_media":4573,"menu_order":36,"template":"","meta":{"cl_author_id":0,"ap_case_type":"EB-1A","ap_applicant":"\u00c7ocuk Romatolo\u011fu, Doktor \u00d6\u011fretim \u00dcyesi ve Klinik Ara\u015ft\u0131rmac\u0131","ap_focus_label":"Uzmanl\u0131k Alan\u0131","ap_focus":"\u00c7ocuk Romatolojisi, Otoinflamatuvar Hastal\u0131klar, Tedavi Yan\u0131t\u0131n\u0131n \u00d6ng\u00f6r\u00fclmesi ve Dijital Sa\u011fl\u0131k","ap_approval_type":"I-140 G\u00f6\u00e7men Dilek\u00e7esi Onay\u0131","ap_notice":5374,"ap_profile":"[[\"Ba\u015fvuru T\u00fcr\u00fc\",\"EB-1A\"],[\"Ba\u015fvuru Sahibi\",\"\u00c7ocuk Romatolojisi Uzman\u0131, Doktor \u00d6\u011fretim \u00dcyesi ve Klinik Ara\u015ft\u0131rmac\u0131\"],[\"Uzmanl\u0131k Alan\u0131\",\"\u00c7ocuk Romatolojisi, \u00c7ocuklarda Otoimm\u00fcn ve Otoinflamatuvar Hastal\u0131klar\"],[\"Ara\u015ft\u0131rma Konular\u0131\",\"Tedavi Yan\u0131t\u0131, Biyolojik Tedaviler ve Dijital Sa\u011fl\u0131k\"],[\"Onay T\u00fcr\u00fc\",\"I-140 G\u00f6\u00e7menlik Ba\u015fvurusu Onay\u0131\"]]","ap_card_title":"\u00c7ocuk Romatolojisi Uzman\u0131na EB-1A Onay\u0131","ap_hide_notice":"","footnotes":""},"approval_type":[33],"approval_region":[37],"class_list":["post-3720","approval","type-approval","status-publish","has-post-thumbnail","hentry","approval_type-eb-1a","approval_region-us"],"_links":{"self":[{"href":"https:\/\/celiksoylaw.com\/tr\/wp-json\/wp\/v2\/approval\/3720","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/celiksoylaw.com\/tr\/wp-json\/wp\/v2\/approval"}],"about":[{"href":"https:\/\/celiksoylaw.com\/tr\/wp-json\/wp\/v2\/types\/approval"}],"version-history":[{"count":4,"href":"https:\/\/celiksoylaw.com\/tr\/wp-json\/wp\/v2\/approval\/3720\/revisions"}],"predecessor-version":[{"id":5375,"href":"https:\/\/celiksoylaw.com\/tr\/wp-json\/wp\/v2\/approval\/3720\/revisions\/5375"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/celiksoylaw.com\/tr\/wp-json\/wp\/v2\/media\/4573"}],"wp:attachment":[{"href":"https:\/\/celiksoylaw.com\/tr\/wp-json\/wp\/v2\/media?parent=3720"}],"wp:term":[{"taxonomy":"approval_type","embeddable":true,"href":"https:\/\/celiksoylaw.com\/tr\/wp-json\/wp\/v2\/approval_type?post=3720"},{"taxonomy":"approval_region","embeddable":true,"href":"https:\/\/celiksoylaw.com\/tr\/wp-json\/wp\/v2\/approval_region?post=3720"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}} |